Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1761-1780 of 2,120 trials

HER2-Expressing Ovarian Cancer: Trastuzumab Deruxtecan with Bevacizumab

We are studying a new combination treatment for patients with HER2-expressing ovarian cancer to see if it works better than standard therapy. The trial will assess safety and how well the treatments help manage the disease.

Ovarian Cancer>2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Systemic Sclerosis: Nintedanib and Tocilizumab Study

We are testing a combination of nintedanib and tocilizumab for patients with systemic sclerosis and interstitial lung disease. The goal is to see if this new treatment is more effective than standard therapies.

Systemic SclerosisSystemic Sclerosis with Interstitial Lung Disease1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPulmonologyRheumatology

Crohn's Disease: SAR442970 Study

We are investigating the effects of a new medication, SAR442970, on adults with moderate to severe Crohn's disease. The study aims to see if it helps improve symptoms and overall health compared to a placebo.

Crohn's Disease1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Advanced Non-Small Cell Lung Cancer: MaaT033 and Cemiplimab

We are studying a new treatment combining fecal microbiotherapy with Cemiplimab for patients with advanced NSCLC who have not responded to previous therapies. This trial aims to see if this combination can improve disease control and overall health compared to standard treatments.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

CIDP: Riliprubart Treatment Study

We are studying the long-term safety and effectiveness of riliprubart for individuals with chronic inflammatory demyelinating polyneuropathy. This trial will help us understand how well it works in improving disability and strength.

Chronic Inflammatory Demyelinating Polyneuropathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurology

Mucopolysaccharidosis Type IIIA: JR-441 Infusions

We are evaluating the safety and potential effectiveness of JR-441 infusions for patients with mucopolysaccharidosis type IIIA. This study aims to explore how well this treatment works for this rare condition.

Mucopolysaccharidosis III>2 yearsSafety phase (I)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInternal MedicinePediatrics

Brain Injury and Concussion: Tau Tracer Study

We are investigating whether tau levels in the brain are higher in patients with brain injuries and athletes with concussion symptoms. The study also looks at how these brain levels relate to tau found in blood samples.

Cerebral ConcussionIntracerebral HemorrhageTraumatic Brain Injury>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineNeurology

Cutaneous Melanoma: IMA203 Treatment Study

We are comparing a new treatment called IMA203 with the best available options for patients with advanced skin cancer. This study aims to see if IMA203 is more effective and safe for those who have already been treated.

Skin Melanoma1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Cervical Dystonia: Botulinum Toxin for Back Muscle Activity

We are studying abnormal muscle activity in the back of people with cervical dystonia. The trial will test whether botulinum toxin injections can help improve this condition and what side effects may occur.

Cervical Dystonia>2 yearsMonitoring phase (IV)Standard MedicinesCost ReimbursementInternal MedicineNeurology

Alzheimer's Disease: Tau and Amyloid Brain Imaging Study

We are investigating how tau protein deposits in the brain can help distinguish between Alzheimer's disease and other conditions. This study may provide insights into early diagnosis and disease progression.

Alzheimer's Disease>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteNeurology

Advanced Melanoma: New Treatment Combination

We are studying a new treatment approach for patients with advanced melanoma, combining immune therapies to see if it improves outcomes and reduces side effects. This trial aims to understand how well these treatments work together.

Solid Tumors3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Multiple Myeloma: Fluciclovine PET/CT Imaging Study

We are investigating a new imaging method for multiple myeloma patients to see how it compares to standard imaging. This study aims to understand its effectiveness and safety in detecting the disease.

Multiple MyelomaEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncologyOtolaryngology

Multiple Myeloma: Isatuximab Combination Therapy

We are studying a new treatment combining isatuximab with other medications for patients with newly diagnosed multiple myeloma who cannot undergo a transplant. The goal is to see how effective and safe this treatment is, and how it impacts patients' lives.

Newly Diagnosed Transplant Ineligible Multiple Myeloma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Rectal Cancer: Atezolizumab and Bevacizumab After Radiotherapy

We are studying a new treatment for low- to intermediate-risk rectal cancer to see if it helps prevent disease relapse and preserves organ function. The trial also evaluates the safety of this approach.

Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Multiple Myeloma: ABBV-453 Treatment Study

We are studying the safety and effects of ABBV-453, alone or with other treatments, for adults with multiple myeloma. This research aims to understand how well it works and how it is tolerated by patients.

Multiple MyelomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Advanced Solid Tumors: GSK5733584 with Anti-Cancer Therapies

We are studying a new drug, GSK5733584, combined with other cancer treatments for patients with advanced solid tumors. The trial aims to evaluate its safety and how well it may work in this setting.

Gynecological TumorsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Chronic Hepatitis Delta: BJT-778 vs Bulevirtide

We are studying a new treatment called brelovitug for chronic hepatitis delta infection to see if it works better and is safer than the current treatment, bulevirtide. We also want to understand how it affects patients' quality of life.

Chronic Hepatitis D Infection1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHepatologyInfectious Diseases

Multiple System Atrophy: Lu AF82422 Study

We are testing the medication Lu AF82422 to see if it can slow disease progression in people with Multiple System Atrophy. The study will also look at its effects on overall health and quality of life.

Multiple System Atrophy1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Sarcopenia Treatment: Nandrolone and Therapy

We are studying whether nandrolone, along with physiotherapy and diet, can improve muscle strength in people with sarcopenia. This research aims to find effective treatments for muscle loss.

Sarcopenia≤3 monthsEfficacy phase (II)Standard MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

Ovarian Cancer: Mirvetuximab Soravtansine Study

We are evaluating different dosing schedules of mirvetuximab soravtansine for patients with advanced ovarian, peritoneal, or fallopian tube cancers. This study aims to find the safest and most effective way to administer the treatment.

Advanced Ovarian and Fallopian Tube Cancer6-12 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology